Toluna and Harris Interactive Deliver Weekly Polling for 2022 French Elections
6.4.2022 12:00:00 EEST | Business Wire | Press release
Toluna, the leading consumer insights provider and parent company of Harris Interactive and KuRunData, today announced a joint initiative with Harris Interactive in service of the French Presidential and Legislative elections.
The companies are conducting weekly polling to measure French citizens on their preferred candidates, voting intention, and out-of-polling-station results. Harris Interactive has historically led this polling effort. However, this year, Harris Interactive is officially partnering with its sister company, Toluna, to cover the events. This year’s efforts include over 50 pre-election surveys with over 100,000 people interviewed, as well as 5,000 interviews on election day.
Harris Interactive and Toluna will also partner with leading French TV channel and radio station, M6 and RTL, throughout their coverage of the French elections. Harris Interactive and Toluna experts will first provide estimates of their weekly polling for the first and second rounds of the Presidential election, held Sunday, April 10, 2022, and Sunday, April 24, 2022.
The coverage will be live on M6 and RTL and will also be shared on Toluna and Harris Interactive social media networks from 12:00 PM CEST each election day and continuing throughout the day. The timeline will be as follows:
- 12:00 PM: Initial analysis of voter turnout
- 5:00 PM: Estimates of voter turnout
- 8:00 PM: Initial estimate of Presidential election results
- 8:30 PM onwards: Exclusive insights from “Voting Day” survey fielded by Harris Interactive and Toluna to understand voter motivations and abstentions
- Later in the evening: Refined results in real time
Following the Presidential election, Harris Interactive and Toluna will again work with M6 and RTL to deliver weekly polling for the French Legislative elections on June 12, 2022 and June 19, 2022, providing exclusive analysis and estimations of the French National Assembly’s composition.
The coverage will again feature live on M6 and RTL, available online throughout the evening, as well as on multiple social media channels, including:
- Harris Interactive: harris-interactive.fr / @HarrisInt_FR
- Toluna: tolunacorporate.com / @TolunaCorporate
- M6: groupem6.fr/ @M6, @M6Info, @M6Pro
- RTL: rtl.fr / @RTLFrance
Toluna CEO Frederic-Charles Petit, said: “We are thrilled to bring Toluna and Harris Interactive together to deliver our on-demand, real-time insights as part of this critical initiative in France’s political calendar. This is a great honor, and we look forward to delivering the accurate data the public desires.”
“Citizens today are bombarded with massive amounts of information during the election cycle, and it is essential that they have access to quality data as they evaluate candidates and results. For more than 20 years, Harris Interactive has been proud to deliver some of the most accurate measures of French election results, and we look forward to continuing this tradition in partnership with Toluna,” commented Jean-Daniel Lévy, Senior Vice President of Harris Interactive France and Director of Politics and Opinion Department.
About Toluna
Toluna delivers real-time consumer insights at the speed of the on-demand economy. Harris Interactive simplifies complex decisions with critical consumer intelligence. By fusing Harris’s sector expertise and award-winning research with Toluna’s innovative tools and technology, we strive to push market research toward a better tomorrow.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005266/en/
Contact information
Media Contact
Articulate Communications for Toluna
Audra Tiner
toluna@articulatecomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom